The Association of the British Pharmaceutical Industry (ABPI) called for the UK to remain part of the EU today. The industry group - which represents drug manufacturers - argued that a ‘yes’ vote would mean licensing of medicines in Wales, England and Scotland would have to be conducted by a local agency rather than the EMA.
CEO Mark Thompson said: “If we left the EU this would mean that the licensing of new medicines would have to be handled by a UK agency as well as a European agency.
“Our members have confirmed that the applications for UK license would come after the European license due to the smaller patient population in the UK.”
More to follow...